13-110449695-G-A

Variant summary

Our verdict is Benign. The variant received -21 ACMG points: 0P and 21B. BP4_StrongBP6_Very_StrongBP7BA1

The NM_001846.4(COL4A2):​c.1095G>A​(p.Pro365Pro) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.353 in 1,547,466 control chromosomes in the GnomAD database, including 100,692 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.29 ( 7158 hom., cov: 32)
Exomes 𝑓: 0.36 ( 93534 hom. )

Consequence

COL4A2
NM_001846.4 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: -0.375

Publications

19 publications found
Variant links:
Genes affected
COL4A2 (HGNC:2203): (collagen type IV alpha 2 chain) This gene encodes one of the six subunits of type IV collagen, the major structural component of basement membranes. The C-terminal portion of the protein, known as canstatin, is an inhibitor of angiogenesis and tumor growth. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter. [provided by RefSeq, Jul 2008]
COL4A2 Gene-Disease associations (from GenCC):
  • porencephaly 2
    Inheritance: AD Classification: STRONG, MODERATE Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, G2P
  • COL4A1 or COL4A2-related cerebral small vessel disease
    Inheritance: AD Classification: MODERATE Submitted by: Illumina
  • familial porencephaly
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -21 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.62).
BP6
Variant 13-110449695-G-A is Benign according to our data. Variant chr13-110449695-G-A is described in ClinVar as Benign. ClinVar VariationId is 311119.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BP7
Synonymous conserved (PhyloP=-0.375 with no splicing effect.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.374 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
COL4A2NM_001846.4 linkc.1095G>A p.Pro365Pro synonymous_variant Exon 19 of 48 ENST00000360467.7 NP_001837.2 P08572A0A024RDW8

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
COL4A2ENST00000360467.7 linkc.1095G>A p.Pro365Pro synonymous_variant Exon 19 of 48 5 NM_001846.4 ENSP00000353654.5 P08572

Frequencies

GnomAD3 genomes
AF:
0.285
AC:
43333
AN:
151838
Hom.:
7153
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.128
Gnomad AMI
AF:
0.439
Gnomad AMR
AF:
0.208
Gnomad ASJ
AF:
0.293
Gnomad EAS
AF:
0.267
Gnomad SAS
AF:
0.318
Gnomad FIN
AF:
0.405
Gnomad MID
AF:
0.152
Gnomad NFE
AF:
0.378
Gnomad OTH
AF:
0.263
GnomAD2 exomes
AF:
0.309
AC:
47279
AN:
152798
AF XY:
0.317
show subpopulations
Gnomad AFR exome
AF:
0.121
Gnomad AMR exome
AF:
0.175
Gnomad ASJ exome
AF:
0.276
Gnomad EAS exome
AF:
0.265
Gnomad FIN exome
AF:
0.406
Gnomad NFE exome
AF:
0.372
Gnomad OTH exome
AF:
0.297
GnomAD4 exome
AF:
0.361
AC:
503171
AN:
1395510
Hom.:
93534
Cov.:
35
AF XY:
0.361
AC XY:
248155
AN XY:
687962
show subpopulations
African (AFR)
AF:
0.123
AC:
3852
AN:
31432
American (AMR)
AF:
0.179
AC:
6289
AN:
35200
Ashkenazi Jewish (ASJ)
AF:
0.274
AC:
6890
AN:
25122
East Asian (EAS)
AF:
0.270
AC:
9628
AN:
35642
South Asian (SAS)
AF:
0.329
AC:
26022
AN:
79092
European-Finnish (FIN)
AF:
0.407
AC:
19995
AN:
49174
Middle Eastern (MID)
AF:
0.205
AC:
1074
AN:
5242
European-Non Finnish (NFE)
AF:
0.381
AC:
410503
AN:
1076796
Other (OTH)
AF:
0.327
AC:
18918
AN:
57810
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.466
Heterozygous variant carriers
0
16901
33802
50702
67603
84504
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
12898
25796
38694
51592
64490
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.285
AC:
43341
AN:
151956
Hom.:
7158
Cov.:
32
AF XY:
0.286
AC XY:
21206
AN XY:
74264
show subpopulations
African (AFR)
AF:
0.128
AC:
5314
AN:
41458
American (AMR)
AF:
0.207
AC:
3167
AN:
15282
Ashkenazi Jewish (ASJ)
AF:
0.293
AC:
1015
AN:
3470
East Asian (EAS)
AF:
0.268
AC:
1379
AN:
5148
South Asian (SAS)
AF:
0.319
AC:
1537
AN:
4814
European-Finnish (FIN)
AF:
0.405
AC:
4268
AN:
10542
Middle Eastern (MID)
AF:
0.167
AC:
49
AN:
294
European-Non Finnish (NFE)
AF:
0.378
AC:
25664
AN:
67930
Other (OTH)
AF:
0.260
AC:
548
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.502
Heterozygous variant carriers
0
1513
3027
4540
6054
7567
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
444
888
1332
1776
2220
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.335
Hom.:
4650
Bravo
AF:
0.260
Asia WGS
AF:
0.278
AC:
970
AN:
3478

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Apr 12, 2018
GeneDx
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -

Porencephaly 2 Benign:2
Jul 22, 2021
Genome-Nilou Lab
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.62
CADD
Benign
3.6
DANN
Benign
0.79
PhyloP100
-0.38
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs76425569; hg19: chr13-111102042; COSMIC: COSV64626275; API